Cardioprotection by resveratrol – weight of evidence

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the United States and it is most frequently manifested as atherosclerosis (AS) of the major arteries. In spite of intense research on AS using a combination of laboratory, animal, and clinical studies, understanding of its etiology is still incomplete; hence, the need for management and prevention remains imperative. AS is initiated by endothelial cell (EC) injury whereas its progression is promoted by EC interaction with cells that are recruited to the injured endothelium, and additionally, bioactive cytokines and chemokines elaborated by the intercellular interplay. A primary research interest of our laboratory has been the mechanisms that underlie the “French paradox” – an epidemiological association of the co-existence of risk factors with low CVD incidence/mortality rates postulated to attribute to low-to-moderate consumption of red wine and grape-derived polyphenol resveratrol. This review summarizes effects and targets of resveratrol in cultured human aortic and pulmonary aortic endothelial cells (HAEC and HPAEC) and animal tissues, with focus on the resveratrol target protein RTP, N-ribosylhydro-nicotinamide:quinone oxidoreductase (NQO2).

Keywords: Resveratrol, cardioprotection, RTPs (resveratrol target proteins), human endothelial cells, wistar rat tissues

Cardioprotection by resveratrol – weight of evidence

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the United States and it is most frequently manifested as atherosclerosis (AS) of the major arteries. In spite of intense research on AS using a combination of laboratory, animal, and clinical studies, understanding of its etiology is still incomplete; hence, the need for management and prevention remains imperative. AS is initiated by endothelial cell (EC) injury whereas its progression is promoted by EC interaction with cells that are recruited to the injured endothelium, and additionally, bioactive cytokines and chemokines elaborated by the intercellular interplay. A primary research interest of our laboratory has been the mechanisms that underlie the “French paradox” – an epidemiological association of the co-existence of risk factors with low CVD incidence/mortality rates postulated to attribute to low-to-moderate consumption of red wine and grape-derived polyphenol resveratrol. This review summarizes effects and targets of resveratrol in cultured human aortic and pulmonary aortic endothelial cells (HAEC and HPAEC) and animal tissues, with focus on the resveratrol target protein RTP, N-ribosylhydro-nicotinamide:quinone oxidoreductase (NQO2).

Keywords: Resveratrol, cardioprotection, RTPs (resveratrol target proteins), human endothelial cells, wistar rat tissues

The “response-to-injury” hypothesis by Ross in the 1970’s posited that AS is initiated by recurrent episodes of injury to the endothelium by a myriad of risk factors; notably, cigarette smoking, hypercholesterolemia, and high blood pressure [1]. Damage to the endothelium induces multiple changes in the vessel architecture and blood components, as exemplified by an increase in hemodynamic flow, recruitment and attachment of leukocytes and platelets, migration of smooth muscle cells to the intima, and deposition of extracellular matrix, which collectively contribute to thrombus formation and eventual occlusion of the vessel (Figure 1).

A progressive decline in age-adjusted CVD-related mortality over the past few decades has been reported in the United States, due to advances in anti-CVD strategies and also to the discovery of dietary agents with cardioprotective activities. Since 1998, research activities in this laboratory have focused on cardioprotection by grape-derived polyphenol, resveratrol, in large part to address the French paradox – the epidemiological phenomenon linking co-existence of CVD risk factors with low incidence/mortality rates which purportedly may attribute to low-to-moderate consumption of red wine and alcoholic beverages [2, 3]. Our studies have shown that resveratrol: i) inhibits oxidation of low density lipoprotein (LDL) isolated from normotensive individuals [4-6], ii) suppresses platelet
aggregation [7-9], ii) reduces in ADP-induced platelet aggregation rate in rabbits [7, 10], iii) inhibits human and rabbit smooth muscle cell (SMC) proliferation in vitro, in response to stimulation by PDGF, endothelin, angiotension II, and serum-mitogens [11-13], iv) reduces EC proliferation [14-16], v) attenuates intimal thickening following endothelium denudation in rabbits [17, 18] and reduces the mean area of atherosclerotic plaques [19], and vi) dose-dependently increases the protein expression of tumor suppressor gene p53, heat shock protein HSP27, quinone reductase 1 and 2, and induces nitric oxide synthase and its altered subcellular distribution [20]. Together, these results support cardioprotection by resveratrol acting by a plethora of activities impinging on events key to AS and CVD and reinforcing the notion that age-adjusted CVD deaths may be independently modulated by diet-based strategies including use of resveratrol.

**Identification of RTPs (resveratrol target proteins) in bovine pulmonary aortic endothelial cells (BPAEC) and tissues from different age Wistar rats**

To determine the mechanism of cardioprotection by resveratrol we advanced the hypothesis that resveratrol acts through interaction with distinct resveratrol target proteins, denoted RTPs. By using an affinity purification strategy in which column immobilized resveratrol serves as the RTP-retention bait, in combination with Matrix Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry and cloning, we identified quinone reductase NQO2 as a specific RTP with a high affinity for resveratrol (K_D ≤ 50 nM) [20-23].

Since proliferation of BPAEC was significantly suppressed by resveratrol in a time- and dose-dependent manner [14, 15] (Figure 2A), we tested the presence of RTPs in cultured BPAEC using the resveratrol-directed affinity chromatography approach. Passage 4-6 BPAEC (obtained from Dr. Olson in this department) was grown to 70% confluence, and treated for 48 h with 25 and 100 µM resveratrol. Cells were harvested after 48 h treatment and lysates were prepared using our previously published procedures. Extracts containing 1 mg protein from control and treated cells were individually applied to mini-columns each containing 0.2 ml of resveratrol-coupled agarose resin. Each column was sequentially eluted with NaCl, ATP and resveratrol [15, 20, 21]. The ATP and resveratrol eluates were concentrated and resolved on 10% SDS-PAGE, followed by silver staining. Figure 2B depicts the stained protein patterns. Treatment with resveratrol resulted in prominent suppression (RTP-59) and slight induction (RTP-22) of proteins. Since both proteins appeared in the fraction eluted with resveratrol, it is evident that they bound avidly with high affinity to the resveratrol column. Interestingly, several silver stained proteins in the ATP-eluted fraction from the 25 µM resveratrol-treated cell extract displayed a profile distinct from a similarly eluted fraction of the control extract. RTP-22 was shown to be NQO2 with a high affinity for resveratrol [20, 21, 24].
To further explore the versatility of resveratrol affinity column approach, its ability for fractionating extracts prepared from animal tissues was investigated. Studies were performed using several tissues, respectively, aorta, heart, kidney and liver, isolated from different age male Wistar rats (40 days and 8 months, from Charles River Laboratories). Homogenates were prepared from tissues and fractionated on resveratrol affinity column, as described. Figure 3A shows results of silver stained bands in the resveratrol-eluted fraction (with and without prior competition with excess resveratrol). Several interesting results are evident in these experiments: i) RTP-22 was below detection in the aorta in both age rats, ii) RTP-22 was most prominent in the liver and kidney among 4 tissues tested and appeared to decrease in 8-month rats, compared to 40-day rats, iii) RTP-22 was detected in the heart extract fractionated on resveratrol affinity column; the intensity of silver-stained RTP-22 appeared to be slightly less in 8-month-old rats. Evidence of decreased expression of RTP-22 as NQO2 in 8-month rat heart compared to 40-day rat heart was obtained by immunoblot analysis (Figure 3B) and enzyme activity assays (Figure 3C). The observed data show that rat tissues are appropri-
Cardioprotection by resveratrol: a review

Presence of RTPs and may be suitable in feeding experiments using resveratrol, red wine extracts and other dietary agents with potential cardioactive properties. It is also noteworthy that results using animal tissues further confirm the utility and sensitivity of this biospecific affinity platform as a quick, cost-effective, and reproducible method for profiling protein patterns exhibiting differential binding properties to resveratrol.

**Uptake of \[^{3}H\]resveratrol in cultured human aortic endothelial cells**

Presence of RTPs in BPAEC and animal tissues suggests that resveratrol is readily taken up in responsive cell types. This possibility was tested using cultured HAEC obtained from commercial sources (Lonza Walkersville Inc., Walkersville, MD, USA). Subconfluent cells maintained in Clonetics EGM-2 BulletKit containing endothelial cell basal medium-2 and growth supplements as recommended by the manufacturer were treated for 2 days with 0, 5, 10, 25, and 50 µM resveratrol. Control and treated cells were incubated with 5 nM \[^{3}H\]resveratrol (specific activity, 15 Ci/mmol), from Moravek Biochemicals (Brea, CA, USA) for 0, 5, 10, and 20 min in serum-free medium at 37°C, 95% humidity and 5% CO₂. At the end of the labeling period, cells were harvested, washed three times with ice-cold phosphate buffered saline to remove unincorporated resveratrol. Attached cells were lysed with 1 ml 0.1 N NaOH. The amount of cell-associated radioactivity was determined by mixing the pooled cell lysates containing 6-16 mg soluble proteins with 4 ml of scintillation cocktail, Liquiscint (National Diagnostics, Atlanta,
GA, USA), and counting using a liquid scintillation counter (Beckman LS 6500, Jersey City, NJ, USA). Figure 4A showed \[^{3}H\]resveratrol bound to HAEC extracts when labeling was immediately terminated by harvesting (within 1 min) and processing (within 2 min), suggesting that there was an initial, rapid association of \[^{3}H\]resveratrol with cellular components. By following the amount of radioactivity in cell extracts after 5, 10 or 20 min of labeling, it can be seen that uptake of \[^{3}H\]resveratrol increased progressively in both control and resveratrol-pretreated HAEC (Figure 4A). Uptake of resveratrol may be further modulated by resveratrol since in HAEC cells pretreated with increasing doses (5-50 µM) of unlabeled resveratrol for 2 days, the uptake of \[^{3}H\]resveratrol into treated HAEC increased in a dose-dependent manner up to 25 µM, more substantially than the control, (Figure 4B), suggesting that pretreatment may affect the cell membrane properties in ways that stimulated the uptake of resveratrol.

It is also noteworthy that in control HAEC, the uptake of radioactive resveratrol within the first 10 minutes was more rapid and robust, and is followed by a steady, maintenance level of labeled resveratrol from 10-20 min (Figure 4A). These results are consistent with the existence of a membrane-associated transport mechanism for resveratrol.

Subcellular distribution of resveratrol in HAEC, HPAEC and AOSMC

Determination of the intracellular disposition of resveratrol is of interest since it might provide information on the identity and nature of cellular targets with which resveratrol binds specifically. We analyzed the intracellular localization of resveratrol in HAEC, HPAEC and AOSMC. Cells were incubated with \[^{3}H\]resveratrol for 10 min, harvested and lysed. Fractionation of the lysate from control and treated cells was performed using the Subcellular Proteome extraction kit, into four cellular compartments, respectively, F1 (cytosol), F2 (membrane/organelle), F3 (nucleus), and F4 (cytoskeleton). Protein content of cell lysates and cellular fractions was determined by coomassie protein assay kit (Pierce, Rockford, IL, USA) with BSA as standard.

The amount of radioactive resveratrol in each compartment was determined. In parallel experiments, we also tested whether the subcellular distribution of this polyphenol may be altered by prior exposure of cells for 2 days to 25 µM resveratrol. Figure 5 shows that i) distribution of radioactive resveratrol in untreated HAEC was different from partitioning of resveratrol in HPAEC, ii) the subcellular distribution of resvera-
Resveratrol pronouncedly inhibits growth of human aortic endothelial cells (HAEC)

As mentioned previously, EC plays an essential role on AS and CVD; the “response-to-injury” hypothesis introduced by Ross places episodic insults to EC as pivotal events in the initiation of atherogenesis [25-28]. Accordingly, prevention of injury distinct from or concurrent with stimulation of repair to damaged endothelium might be intimately involved in mechanism of action of cardioprotective agents. Therefore, we tested the effects of resveratrol on proliferation of cultured HAEC. Subconfluent cells maintained in Clonetics®EGM®-2 BulletKit® containing endothelial cell basal medium-2 and growth supplements as recommended by the manufacturer were treated with 0, 1, 10, 25, and 50 mM resveratrol. Control and treated cells were harvested at 48 h. Growth and viability was determined using a hemocytometer and by the trypan blue exclusion assay. Figure 6 shows that proliferation of HAEC (panel A) was inhibited by resveratrol in a concentration-dependent manner, and at the highest concentration of 50 µM.
resveratrol tested, also accompanied by substantial cell death (panel B). Next, immunoblot analysis was performed to examine changes in levels of several key proteins playing a critical role in the regulation of cell growth and death. These results are presented in the lower panel in Figure 6. Evidently, a concentration-dependent decrease in expression of PCNA and cyclin D1, NFkBp65 was observed. Notably, the 50 µM resveratrol-treated HAEC was also accompanied by an increase in AIF expression.

Resveratrol exerts a less prominent growth inhibitory effect on human pulmonary aortic endothelial cells (HPAEC)

Recent studies show that heterogeneity is intrinsically present among endothelial cells derived
from anatomically distinct sites [29-33], and additionally, also from different species [34]. Endothelial cells from different vascular locations may also exhibit strikingly different responses when exposed to identical physical and biological challenges [35-46]. Furthermore, a remarkable focal distribution has been found in vascular diseases, suggesting that the function and regulatory response of endothelial cells to risk as well as protective factors may be contingent upon the source of the vasculature from which endothelial cells originate. Therefore, the effects of resveratrol on growth of cultured commercially available HPAEC was also performed, by exposing cells to an increasing concentration of the grape polyphenol, respectively, at 1, 10, 25, and 50 µM. At 48 h post treatment, cells were harvested for assessment of growth and viability, using the trypan blue exclusion assay. Figure 7 shows that proliferation of HPAEC was inhibited less significantly by resveratrol compared to HAEC; moreover, little effect of resveratrol on PCNA expression was observed. Of note, inhibition on cyclin D1 and NFKBp65 and stimulation on AIF in resveratrol-exposed HPAEC, was much more modest, compared to similarly treated HAEC (Figure 6).

Summary and conclusion

Red wine polyphenols have been proposed to confer protection against CVD. In this review, we have summarized data showing that biologically active red wine polyphenol, resveratrol acts by a plethora of activities and putative molecular targets (Figure 8), in support of its role as a deterrent targeting the endothelium and contributing to prevention of AS. Additional studies to determine the mechanism of cardioprotection by resveratrol may further advance the development of diet-based strategies to reduce the adverse health effects of risk factors on the endothelium and CVD.

Acknowledgements

Studies on cardioprotection by resveratrol in our laboratory since 1998 had been supported by: California Grape Trade Commission, Phillip Morris USA Inc. and Phillip Morris International, and the Intramural Sponsored Research Program of New York Medical College to JMW.

Address correspondence to: Joseph M. Wu, MD, PhD, Room 147, Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA, Phone: 914-594-4891; Fax: 914-594-4058; E-mail: Joseph_Wu@nymc.edu

References

Cardioprotection by resveratrol: a review


